drug · antibody
trontinemab
Phase 3updated 6mo agoby F. Hoffmann-La Roche Ltd🔗 ChEMBL
Phase 3community read0 votes
Antibody drug with a maximum clinical stage of Phase 3, with 1 investigational indication.
indications
indications
Alzheimer's Disease
all catalysts(0)
nothing on the calendar yet
Trials studying trontinemab
- phase3A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
- phase3A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
- phase3A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
News(7)
- Alzheimer’s field looks beyond amyloid as biopharma converges at CTAD 2026This week, biopharma companies including Biogen, Bristol Myers Squibb and Roche are in Boston with new data on their efforts to tackle Alzheimer’s disease.biospace · 1d ago
- Opinion: STAT+: What it’s like to live with cognitively unimpaired Alzheimer’s diseasePeople with cognitively unimpaired Alzheimer’s “may be asymptomatic, but they do have a disease experience,” writes Jason Karlawish.stat · 11d ago
- Genentech pens $1.27B deal to access Alector’s preclinical blood-brain barrier assetAfter a series of clinical-stage failures, Alector is resetting around its preclinical blood-brain barrier delivery technology, securing a big pharma partnership along the way.biospace · 1mo ago
- ‘We’re so close to the tech companies’: Genentech CEO talks Fierce through vision for the futureWhen recombinant DNA pioneer Herbert Boyer, Ph.D., first got a call from venture capitalist Robert Swanson about starting a company, the savvy scientist wasn’t sure a meeting would be worth his time.fiercebiotech · 1mo ago
- BMS’ neuro renaissance was built on back of Celgene mega-mergerWell-known for its oncology efforts and making recent headlines for a rumored mega merger with AstraZeneca, Bristol Myers Squibb is also dedicating considerable resources to neurological and psychi…biospace · 2mo ago
- Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the storeWith so many unknowns, Biogen is carefully eyeing its next-gen Alzheimer’s treatment diranersen as a high-risk, high-reward project with the potential for a major payout around 2030.biospace · 3mo ago
- Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add onRoche has 19 investigational medicines that could launch by 2030—and even if not all of them make it to market, the company is “well set-up for growth into the next decade,” CEO Thomas Schinecker s…biospace · 3mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that